Immunic CEO details progress following productive third quarter

Proactive - Interviews for investors

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through key developments, emphasising an active third quarter. Vitt highlighted the continuation of Phase 3 ENSURE trials in relapsing multiple sclerosis (MS), and a successful interim analysis that confirmed the studies' progress. He also mentioned the Phase 2 CALLIPER study in progressive MS, with crucial data expected next April to assess the neuroprotective benefits of vidofludimus calcium. Additionally, Vitt pointed out Immunic’s strengthened team, featuring new members like Simona Skerjanec and Jason Tardio, whose extensive experience in MS drugs and commercial operations positions the company for future growth. Notably, Immunic maintains a solid cash position, projecting sufficient funds into the third quarter of next year. Key achievements included a successful R&D day in New York, underlining Immunic’s commitment to research and innovation. Stay tuned to Proactive's YouTube channel for more updates, and don't forget to like, subscribe, and turn on notifications for future content. #ImmunicTherapeutics #MultipleSclerosis #Phase3Trials #BiotechUpdates #VidofludimusCalcium #PharmaNews #ClinicalTrials #MSResearch #InvestingInHealth #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews